DATE: January 17, 2023

FROM: Haecin Chun, MS, Consumer Safety Officer
Bioresearch Monitoring Branch (BMB)
Division of Inspections and Surveillance (DIS)
Office of Compliance and Biologics Quality (OCBQ)

THROUGH: Dennis T. Cato, Branch Chief, BMB

THROUGH: Carrie M. Mampilly, MPH, Director, DIS

TO: Zuben Sauna, PhD, Chair, BLA 125771/0
Megha Kaushal, MD, Clinical Reviewer
Niloofar Kennedy, MS, RPM

SUBJECT: Bioresearch Monitoring (BIMO) Final Discipline Review Memo

SPONSOR: Bioverativ Therapeutics Inc.
PRODUCT: efanesoctocog alfa (ALTUVIIIO)
Application: BLA STN 125771/0

FINAL SUMMARY STATEMENT:
BIMO inspection assignments were issued for one domestic and three foreign clinical study sites participating in the conduct of Protocols EFC16293. The inspections did not reveal issues that impact the data submitted in this Biologics License Application (BLA).

BACKGROUND:
Four BIMO Clinical Investigator (CI) inspection assignments were issued in support of this BLA. The clinical study sites were selected based on subject enrollment, previous inspection history, as well as the data and information submitted in BLA 125771/0.

The inspections focused on the pivotal study EFC16293 entitled, "*A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients ≥12 Years of Age With Severe Hemophilia A.*"

The inspections were conducted in accordance with FDA's Compliance Program (CP) 7348.811, Inspection Program for CI. Information and data submitted in the BLA were compared to source documents at each inspected site. The inspection assignments also included specific questions concerning the pivotal study.

INSPECTION SUMMARY AND OUTCOME:
No significant objectionable inspectional findings were observed during the inspection. The table below summarizes the BIMO inspections:

Site #	Study Site Name and Location	FDA Form 483 Issued?	Final Inspection Classification
139	Arbesu Hematology Institute Godoy Cruz, Argentina	No	No Action Indicated (NAI)
283	Lille University Hospital Center Heart-Lungs Institute Hemostasis and Transfusion Department Lille, France	No	NAI
122	Royal Prince Alfred Hospital Sydney, Australia	No	NAI
908	Michigan State University Center for Bleeding & Clotting Disorders East Lansing, MI, USA	No	NAI

INSPECTION FINDINGS

Sponsor:
No significant sponsor issues were observed during the inspection.

Clinical Investigators:
No significant issues were observed during the CI inspections

FINANCIAL DISCLOSURE:
The CI CP directs the FDA investigator to ask the CI if and when he/she disclosed information about his/her financial interests to the sponsor and/or interests of any sub-investigators, spouse(s) and dependent children, and if and when the information was last updated. The information submitted to the BLA was verified for each of the inspected clinical sites.

ADMINISTRATIVE FOLLOW-UP:
Post inspection correspondence were issued for the inspected parties.

Should you have any questions or comments about the contents of this memo or any aspect of Bioresearch Monitoring, please contact me at 240-402-8038.

_____
Haecin Chun
Consumer Safety Officer